Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil OKs fast-track for device and pharma trial applications

This article was originally published in Clinica

Executive Summary

Brazilian proposals to fast-track the licensing-assessment of a large proportion of the clinical trial applications it receives have been approved. Pending the formal publication of the enacted resolution by regulatory agency Anvisa and the precise detail of the policy, the government has issued a statement confirming that applications involving trials already approved in the EU, US, Japan, Australia or Canada will be fast-tracked. As described in a public consultation in May (www.clinica.co.uk, 10 May 2012), the measure is expected to halve the approval time: an estimated 80% of all applications would be processed within 90 days, said Anvisa. At the time, Brazil reported a backlog of over 100 applications. The new regulation will not affect the procedure for assessing the ethical aspects of trial applications, which will remain the responsibility of the national research ethics committee, Conep.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel